ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

CEO

Employees

Country

United States

ISIN

US04522R1014

WKN

000A3D7BB

Listings

7A9.MU

0 Comments

Share your thoughts

FAQ

What is ASLAN Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange ASLAN Pharmaceuticals stocks are traded under the ticker 7A9.MU.

How many employees does ASLAN Pharmaceuticals have?▼

As of September 05, 2026, the company has 35 employees.

In which sector is ASLAN Pharmaceuticals located?▼

ASLAN Pharmaceuticals operates in the Technology sector.

When did ASLAN Pharmaceuticals complete a stock split?▼

ASLAN Pharmaceuticals has not had any recent stock splits.

Where is ASLAN Pharmaceuticals headquartered?▼

ASLAN Pharmaceuticals is headquartered in 190 Elgin Avenue, United States.